Tagged with P

cost containment “Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has brought both benefits and shortcomings. One consequence is that Poland has the lowest average price of medicine in the European…

regulation PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high income nation by 2020 and a reference in terms of healthcare quality worldwide.   How would you describe the healthcare…

Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice.   What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…

Portugal In terms of growth, the market began to show signs of improvement in 2012, overall market value has still not recovered from the recession, currently standing at around the same levels as 2002.

R&D Aplicaps was founded in 2008 with solely Spanish investments, when Spain was already suffering from a recession due to the real estate bubble. The company’s CEO, José Luis Martín Guinea, discusses the origins of the company in Portugal and the competitive services that Aplicaps offers to the Spanish pharmaceutical market.…

association Elmer Torres Cortes is General Manager of the Industrial Association of Pharmaceutical Laboratories (ASILFA) that was created to defend the interests of the generic and local manufacturers. Cortes speaks about the developments of the Chilean pharmaceutical industry.   What are the main drivers and challenges for the Chilean pharmaceutical industry…

clinic “Clinica Alemana’s objective is to be the most patient-centric clinic and we take that very seriously. Therefore, we constantly strive to provide the most modern technology, the best infrastructure and, above all, the highest-qualified and most caring professionals in order to satisfy all our patients’ healthcare needs”, says Clinica Alemana’s…

Biosano “A company active in the Chilean pharmaceutical market has to reinvent its business model every three years because today we are competing against some of the largest multinationals.”     How has the company developed over the past years? Chile has a very open and transparent market, which requires companies to…

Spain Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma Spain, discusses the challenges in adapting to the country’s regional peculiarities and the subsidiary’s greater commitment to a much more stakeholder-focused approach. What were…

plasma market In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains one of the most important players in Europe’s highly competitive plasma-derived product market. Luis Cruz, general manager of CSL Behring…

plasma market In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains one of the most important players in Europe’s highly competitive plasma-derived product market. Luis Cruz, general manager of CSL Behring…

Poland Thanks to its strategic location, EU membership, and low cost base, Poland has successfully attracted investments from the global pharmaceutical industry. Today, over half of the top 30 pharma companies operating in Poland have manufacturing facilities or functional hubs (IT center, Clinical research, Shared Services, etc) in the country.